Evolus(US:EOLS)2022-11-07 16:00Financial Performance - Jeuveau sales net revenues increased by $7.2 million, or 27.0%, to $33.9 million for the three months ended September 30, 2022, compared to $26.7 million for the same period in 2021, primarily due to higher sales volumes [206]. - Total net revenues for the three months ended September 30, 2022, were $33.9 million, up from $26.7 million in the same period of 2021 [204]. - Gross profit for the three months ended September 30, 2022, was $19.7 million, with a gross profit margin of 58.0%, compared to a gross profit of $14.5 million and a margin of 54.2% in the same period of 2021 [203]. - Product revenue increased by $40.0 million, or 61.5%, to $105.0 million for the nine months ended September 30, 2022, compared to $65.0 million for the same period in 2021 [218]. - Gross profit margin decreased to 57.4% for the nine months ended September 30, 2022, compared to 93.2% for the same period in 2021 [221]. - Net loss was $61.2 million for the nine months ended September 30, 2022, compared to a net loss of $28.6 million for the same period in 2021 [232]. Operating Expenses - Operating expenses for the three months ended September 30, 2022, totaled $51.8 million, compared to $45.8 million in the same period of 2021 [204]. - Selling, general and administrative expenses increased by $26.3 million, or 33.4%, to $105.1 million for the nine months ended September 30, 2022, from $78.8 million for the same period in 2021 [222]. - Research and development expenses increased by $1.8 million, or 112.5%, to $3.4 million for the nine months ended September 30, 2022, from $1.6 million for the same period in 2021 [223]. - Non-operating expense, net, increased by $5.2 million, or 400.0%, to $6.5 million for the nine months ended September 30, 2022, from $1.3 million for the same period in 2021 [228]. Cash Flow and Liquidity - Cash and cash equivalents as of September 30, 2022, were $65.6 million, with positive working capital of $64.7 million [231]. - Cash used in investing activities was $1.5 million for the nine months ended September 30, 2022, compared to cash provided by investing activities of $4.4 million for the same period in 2021 [252]. - Cash used in financing activities was $2.6 million for the nine months ended September 30, 2022, compared to $25.2 million provided by financing activities in the same period in 2021 [253]. - For the nine months ended September 30, 2022, operating activities used $76.1 million of cash, primarily due to a net loss of $61.2 million and changes in net operating assets and liabilities totaling $32.7 million [250]. - Cash and cash equivalents at the end of the period were $65.6 million, down from $146.3 million at the beginning of the period [249]. Future Outlook - The company expects to receive full TGA regulatory approval for Jeuveau in Australia and launch the product in 2023 [193]. - The company is finalizing plans for entering additional countries in Europe as part of a phased rollout of Jeuveau [193]. - The company anticipates elevated levels of cost inflation to continue, potentially impacting consumer discretionary spending for aesthetic medical procedures [200]. - Research and development expenses are expected to continue increasing as the company seeks to develop further product candidates and pursue regulatory approvals in other jurisdictions [210]. - The company’s future funding requirements will depend on various factors, including revenue growth for Jeuveau and the success of planned international launches [246]. Obligations and Liabilities - The company has a contingent royalty obligation to the Evolus Founders, requiring quarterly payments of a low single-digit percentage of net sales of Jeuveau until the end of Q2 2029 [199]. - The company recorded an aggregate balance of $45.5 million for future royalty payment obligations to Evolus Founders as of September 30, 2022 [238]. - The company agreed to pay Allergan and Medytox a total of $35.0 million in multiple payments over two years, with $15.0 million paid in Q3 2021 and another $15.0 million in Q1 2022, leaving a remaining $5.0 million due in the next twelve months [239]. - The company has future obligations including a $5.0 million settlement payment related to the Medytox/Allergan Settlement Agreements and ongoing royalty payments to Allergan and Medytox [254]. Economic Conditions - The company’s cash requirements may be impacted by potential disruptions to the supply chain, inflation, and other economic conditions [243]. - The company’s projections of capital requirements are based on assumptions that may prove to be incorrect, potentially necessitating additional capital raising efforts [245]. - The company’s operating lease for its headquarters in Newport Beach, California, is a five-year non-cancelable lease expiring on January 31, 2025 [241].